Development and Evaluation of Thermo Triggered in Situ Nasal Gel of Selegiline for Depressive Disorders: In Vitro, in Vivo and Ex Vivo Characterization

In present scenario selective serotonin reuptake inhibitors are the first-choice drug for depression, but as per study of American Psychiatric Association monoamine oxidase inhibitor may be used as an antidepressant when other antidepressant trial on patient have been failed. Selegiline is both MAO-A and MOA-B inhibitor (dose dependent). Present delivery system is an in situ gelling system based on the chitosan and β-glycrophosphate. β-Glycerophosphate is used in form of di sodium salt which is a weakly basic compound which is naturally found in the body. In situ gelling system was prepared by addition of β- glycerophosphate to chitosan polymer causes conversion of pH sensitive chitosan to temperature sensitive. Developed formulations were evaluated for mucoadhesive strength, gel strength, drug content, in vitro release which was found 17.0±1.0 seconds, 6.4±0.1, 229.3±1.0 cp, 1433.3±1.2 cp, 99.45±0.4 %, 35.7±0.6 seconds, 3035.78±0.46 dyne/cm² respectively. Histopathological studies of treated nasal mucosa of sheep revealed that selected formulation batch have no toxic effect on mucosal layer and no significant change was observed in mucosal structure. In vivo study of prepared optimized in situ gel was found more efficacious compare to marketed oral tablet of selegiline.